The market for chemiluminescence immunoassay (CLIA) analyzers is anticipated to grow from a worth of US$ 6.4 billion in 2023 to US$ 12 billion by the end of 2033, expanding at a CAGR of 6.5%.
In addition to the increase in hospital visits brought on by the rising frequency of infectious diseases, hospitals are favoured by patients, resulting in a significant need for chemiluminescence immunoassay solutions in hospital settings.
Chemiluminescence is defined as the emission of light during a chemical reaction without the significant generation of heat. A particular class of light detector known as a “chemiluminescence immunoassay analyzer” was created with the express purpose of measuring the formation of antigen-antibody complexes through light emission.
Download Free Sample Copy of This Report
Why are Sales of Chemiluminescence Immunoassay Analyzers Increasing Rapidly across the World?
Doctors and pathologists operating in in-patient or out-patient settings of the chemiluminescence immunoassay analyzers market place a major emphasis on the increasing rate of assay standardisation. The main objective of calibrating the assays is to compare the test results to the established standards before giving test results to patients.
Analyzers for chemiluminescence immunoassays are made in accordance with regulations’ defined specifications. The makers of chemiluminescence immunoassay analyzers also offer internal reference standard material to make their results more comparable to those of other manual test procedures.
In the field of clinical diagnostics, the chemiluminescence immunoassay technique is frequently employed to pinpoint chronic disorders. These chronic diseases are the main causes of disability and mortality worldwide.
Why High use of Automated CLIA Analyzers in North America?
Market share for chemiluminescence immunoassay analyzers in North America is 50%. The need for multiplexed and automated CLIA analyzers is increasing as a result of the rise in the demand for specialised diagnoses to enable quick decision-making. The regional market is also predicted to grow as a result of an increase in government financing for R&D efforts connected to chemiluminescence immunoassays.
Due to the high need for point-of-care, home healthcare, and quick diagnostic tests as well as the existence of leading chemiluminescence immunoassay analyzer manufacturers and suppliers, the chemiluminescence immunoassay analyzer market in the United States is predicted to expand quickly. The presence of a sophisticated healthcare infrastructure and the increasing prevalence of chronic diseases are major market growth drivers.
According to the American Academy of Dermatology Association, more than 1 million People are battling melanoma. Due to the increasing demand for effective diagnosis and treatment methods, chemiluminescence immunoassay processes are being used more frequently.
Which Application Will Bring in High Revenue Streams?
According to application, the market is segmented into endocrine disorders, cancer, infectious diseases, hepatitis and retrovirus, cardiovascular disorders, allergies, autoimmunity, drug discovery & development, and others. Chemiluminescence immunoassay analyzers are becoming more popular in oncology due to rising cancer prevalence and early detection of the disease.
The increase in cancer instances globally has encouraged R&D for the disease’s detection, diagnosis, and therapy. Because it is one of the most frequently diagnosed rare diseases, the development of cancer therapies and diagnostic techniques continues to be a key focus for scientists and researchers.
Chemiluminescence immunoassay analyzers are increasingly in demand for oncology studies. Many studies have shown that the use of brand-new and verified biomarkers can lead to the early diagnosis of a variety of cancers. It is predicted that this will encourage segment growth.
Key Companies Profiled
- Abbott Laboratories
- Beckman Coulter, Inc.
- Roche Holding AG
- Sysmex Corporation
- Randox Laboratories Ltd.
- Tosoh Corporation
- Immunodiagnostic Systems
- Inova Diagnostics, Inc.
- Siemens Healthineers
Subscribe Newsletter for the Latest Updates